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Patient with primary immune deficiency
Rubella-positive granuloma
A B S T R A C T
Persistent rubella virus (RV) infection has been associated with various pathologies such as congenital rubella
syndrome, Fuchs's uveitis, and cutaneous granulomas in patients with primary immune deficiencies (PID).
Currently there are no drugs to treat RV infections. Nitazoxanide (NTZ) is an FDA-approved drug for parasitic
infections, and has been recently shown to have broad-spectrum antiviral activities. Here we found that empiric
2-month therapy with oral NTZ was associated in the decline/elimination of RV antigen from lesions in a PID
patient with RV positive granulomas, while peginterferon treatment had no effect. In addition, we characterized
the effects of NTZ on cell culture models of persistent RV infection. NTZ significantly inhibited RV replication in
a primary culture of human umbilical vein endothelial cells (HUVEC) and Vero and A549 epithelial cell lines in a
dose dependent manner with an average 50% inhibitory concentration of 0.35 μg/ml (1.1 μM). RV strains
representing currently circulating genotypes were inhibited to a similar extent. NTZ affected early and late stages
of infection by inhibiting synthesis of cellular and RV RNA and interfering with intracellular trafficking of the RV
surface glycoproteins, E1 and E2. These results suggest a potential application of NTZ for the treatment of
persistent rubella infections, but more studies are required.
1. Introduction
Rubella virus (RV) is a small, enveloped virus with a positive single-
stranded RNA genome (family Togaviridae, genus Rubivirus). RV is an
important human pathogen because of its ability to cause multiple
pathologies after establishing persistent infections in immune privi-
leged body sites or in fetuses during the first trimester of pregnancy.
Persistent infections in a fetus, which has an immature immune system,
can result in multiple birth defects called congenital rubella syndrome
(CRS) (Driscoll, 1969; Plotkin et al., 2011; Tondury and Smith, 1966).
Post-rubella encephalitis, often fatal, has been documented following
persistent infections in the brain with both wild type and vaccine
viruses (Chaari et al., 2014; Guler et al., 2009; Wolinsky et al., 1982).
Chronic recurrent rubella-associated arthritis can develop after im-
munization of adults (Fraser et al., 1983; Tingle et al., 1985). Granu-
lomas in persons with primary immune deficiencies (PID) and Fuchs's
uveitis are newly suggested diseases associated with decades-long
persistent RV infections (Abernathy et al., 2015; Bodemer et al., 2014;
Doan et al., 2016; Perelygina et al., 2016). Currently, there are no an-
tiviral drugs to treat rubella infections and identification of treatments
for chronic rubella diseases will be beneficial.
Nitazoxanide (NTZ) is an FDA-approved drug (licensed in US as
Alinia®) for treatment of enteritides due to parasites, protozoa, and
anaerobic bacteria (Cohen, 2005; Fox and Saravolatz, 2005). NTZ was
also shown to have broad-spectrum antiviral activities and is currently
in Phase II/III clinical trials for hepatitis C, influenza viruses, rotavirus
and norovirus (Korba et al., 2008; Rossignol, 2014; Rossignol et al.,
2009). No significant drug-related health issues have been reported; the
drug is safe and is approved for pediatric use (Cohen, 2005; Fox and
Saravolatz, 2005). NTZ targets host functions that are essential for viral
replication, but are not pathogen-specific. Several anti-viral mechan-
isms have been proposed such as induction of innate immunity,
downregulation of viral receptors or interference with maturation of
viral structural proteins at the post-translational stage, probably due to
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Ca2+ depletion inducing chronic sub-lethal stress in the endoplasmic
reticulum (ER) (Ashiru et al., 2014; Elazar et al., 2009; Gekonge et al.,
2015; Korba et al., 2008; La Frazia et al., 2013; Rossignol et al., 2009;
Trabattoni et al., 2016).
In this study, we investigated the ability of NTZ to control RV re-
plication in cell culture and explored the mechanisms of the anti-RV
activities of NTZ in this system. In vitro studies confirmed that NTZ
inhibited RV replication and NTZ treatment of a PID patient showed
therapeutic efficacy.
2. Material and methods
2.1. Cell cultures, viruses and treatments
Human umbilical vein endothelial cells (HUVEC) (Lonza) were
cultured in Endothelial Growth Medium (Lonza). A549 (ATCC
#CCL185) and Vero cells (ATCC #CCL CCL81) were maintained in
Dulbecco's Modified Eagle Medium (Invitrogen) containing 5% FBS
(Atlanta Biologicals) supplemented with 50 μg/ml gentamicin
(Invitrogen). The vaccine strain RA27/3 and clinical isolates RVi/
Dezhou. CHN/0.02 (RV-Dz), RVi/Seattle. WA.USA/16.00, RVi/
Burlington. MA.USA/44.11, RVi/Yavapai. AZ.USA/4.10, and RVi/
Redmond. WA.USA/18.11 were propagated in Vero cells. Nitazoxanide
(Sigma-Aldrich) was dissolved in dimethyl sulfoxide (DMSO) at a con-
centration of 10 mg/ml. Medium containing 0.1% DMSO was used as a
vehicle control in all experiments.
2.2. Case description
A female patient born in 1986 had received immunization against
measles and rubella at ages 5 and 9 years. Later, she was diagnosed as
having combined immunodeficiency involving defective B- and T-cell
maturation and she had received immunoglobulin replacement treat-
ments. Since 1999, the patient had suffered from chronic skin lesions of
her right hand and arm. Bone and skin biopsies showed granulomatous
histology but no causative infectious agent was identified (Fig. 1A–B).
Frequent empiric treatments for bacteria, mycobacteria and fungi were
given without any significant benefit. In 2015, she was one of the in-
dividuals (patient #1) with PID whose cutaneous granulomas were
discovered to be positive for the vaccine RV strain, RA 27/3 (Perelygina
et al., 2016). In 2015, the patient developed progressive multifocal
leukoencephalopathy (PML) associated with polyomavirus JC (JCV).
The effects of peginterferon alfa-2a and NTZ treatments on controlling
JCV and modifying the PML course has been described in a separate
publication, which also includes the detailed timeline of the treatments
and the description of the patient's immune status (Hautala et al.,
2017). In February 2016, the patient developed septic aspiration
pneumonia resulting in death.
2.3. Ethics statement
Informed consent was obtained from the patient's caregiver by the
attending physician accordingly to standards of practice in Finland.
This project was determined by CDC to be Non-Human Research be-
cause CDC was restricted from access to personal identifying informa-
tion.
2.4. Cytotoxicity and growth inhibition assay
Cells were seeded into 96-well plates at a density of 2 × 104 cells
per well and treated with serially diluted NTZ for 48 h in quadruplicate.
NTZ cytotoxicity and growth inhibition was assessed with a LDH-Based
cytotoxicity detection kit (Roche) using the modified protocol (Smith
et al., 2011).
2.5. Virus infection and titration
Confluent cell monolayers in 48-well plates were infected with RV
at an MOI of 5 pfu/ml unless differently specified. After 1-h virus ad-
sorption, the monolayers were washed three times with PBS and then
treated with NTZ or DMSO. The supernatants were collected at 48 h
post-infection (hpi) and titered on Vero cells by an immunocolorimetric
Fig. 1. RV antigen in lesions of a PID patient. (A)
Cutaneous skin lesions. (B) Hematoxylin and
eosin staining of a cutaneous granuloma. (C)
Histological immunofluorescent staining showing
distribution of RV capsid protein (red) in granu-
lomas and epidermis of the same skin lesion be-
fore and after 2-month treatments with interferon
and oral NTZ spaced one month apart. Nuclei
were stained with DAPI. Multiple clusters of RV-
positive cells were easily detected prior to the
NTZ treatment. Note the lack of RV staining in
the epidermis and a single weakly positive cell
(the white arrow) in the granuloma after the NTZ
treatment. (For interpretation of the references to
colour in this figure legend, the reader is referred
to the web version of this article.)
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plaque assay (Chen et al., 2007). NTZ concentrations producing 50%
and 90% reductions in virus yield (IC50 and IC90) were determined by
interpolation from dose-response curves using Prism (v6.0) software
(GraphPad Software Inc.). For time-of-addition experiments, HUVEC
monolayers were treated with 2.5 μg/ml NTZ for 14, 6 or 3 h before
infection, during the 1-h virus adsorption period or at 0, 3, 6, 14, 18, 24
or 48 hpi with RV at an MOI of 5. Virus yield was determined either at 2
dpi (pretreatment of cultures) or 2 days post-treatment.
2.6. RNA fluorescence in situ hybridization (RNA-FISH)
Cells grown on poly-lysine coated chamber slides (BD Biosciences)
were infected with RV at an MOI of 5 and then treated with 2.5 μg/ml
NTZ for 2 days. RV RNA-FISH using a QuantiGene ViewRNA assay kit
(Affymetrix) has been described (Perelygina et al., 2015). A mixture of
a Cy5-labeled probe set for either negative or positive-strand RV
genomic RNA or influenza negative strand (negative control) and a
FITC-labeled probe set for the peptidylpropyl isomerase B (PPIB) or β-
actin gene was used. Images were taken using an AxioImager A1 system
and AxioVision software (Zeiss, Germany). Fluorescence intensity from
six microscopic fields (40–50 cells per field) was measured using Im-
ageJ (Schindelin et al., 2012).
2.7. Labeling nascent RNA
Newly synthesized RNA was detected using a Click-iT RNA imaging
kit (Invitrogen) according to manufacturer's instructions. Briefly, cells
were treated with either 5 μg/ml NTZ or 0.1% DMSO for 24 h or 10 μg/
ml actinomycin D for 4 h followed by 2-h incubation with 2 mM 5-
ethynyl uridine. The cells were then fixed with 4% paraformaldehyde,
permeabilized with 0.1% triton X-100 and incubated with a Click-iT
reaction cocktail containing Alexa Fluor 488-azide. Fluorescence in-
tensity of the nuclei (n = 50 for each condition) in the microscopic
images was quantitated using ImageJ.
2.8. Immunofluorescence assay (IFA) and Western blot (WB)
IFA and WB analyses of viral antigens were performed as described
(Perelygina et al., 2013) using the mouse monoclonal antibodies spe-
cific for rubella capsid protein (Abcam), E2 glycoprotein (Meridian Life
Science) and E1 glycoprotein (CDC core facility). The percentage of RV
infected cells was quantified by counting E1-positive cells in 10 random
microscopic fields.
2.9. Histological immunofluorescence staining of tissue sections
Immunofluorescence staining of formalin fixed paraffin-embedded
tissue sections was performed as described earlier (Perelygina et al.,
2016).
2.10. Statistical analysis
Statistical analyses were performed with a GraphPad Prizm software
(GraphPad Software Inc.) using the Student's t-test for unpaired data. A
p value of< 0.05 was considered significant.
3. Results
3.1. Decline/elimination of RV from cutaneous lesions of a PID patient
Immunofluorescence staining of the skin biopsies (obtained in 2009,
2011 and 2015) from lesions on the patient's arm revealed the presence
of RV antigen in epidermis and cutaneous granulomas (Fig. 1C). In
2015, granulomas progressed and conventional therapies were in-
effective. An empiric 2-month antiviral treatment with peginterferon
alfa-2a was given according to the hepatitis C regimen (Hoofnagle and
Seeff, 2006). The patient was tired, dizzy and lost her appetite when
high doses of the drug were given. She also developed thrombocyto-
penia. The treatment was discontinued due to adverse reactions of the
drug. One month later, the patient was given 500 mg of oral NTZ twice
daily for two months, which was well tolerated as no obvious negative
side-effects were noted. The effectiveness of the treatments was eval-
uated by immunostaining skin biopsies taken from the same lesion for
RV. While the peginterferon treatment had no effect on the amount and
distribution of RV antigen, the NTZ treatment resulted in almost com-
plete elimination of RV antigen from the lesions. No antigen was de-
tected in the epidermis and only sporadic, weakly stained macrophages
were observed in the sequential sections of the biopsy (Fig. 1C). The
treatment did not provide noticeable clinical improvement in the re-
maining five months of her life. The skin had secondary bacterial in-
fection following the NTZ treatment and the patient was treated with
antibiotics.
3.2. Inhibitory effects of NTZ on RV infection
The effect of NTZ treatments on RV replication was investigated
using the previously described in vitro model of RV persistence, a
HUVEC primary culture. HUVEC monolayers were infected with RV-Dz
at an MOI of 5 and then treated with different concentrations of NTZ or
0.1% DMSO for 48 h. Virus titers in the medium were determined by a
plaque assay. The percentage of infected cells was estimated by
counting E1-positive cells following IFA. We observed a dose-dependent
inhibition of RV production and a concurrent reduction of the number
of RV-positive cells in the NTZ-treated cultures (Fig. 2A–B). There were
only a few positive cells in the wells treated with 2.5–5 μg/ml NTZ,
while almost all cells were positive in the control wells. No positive
cells were observed after the treatment with 10 μg/ml NTZ.
The effects of NTZ treatment on cell viability and proliferation were
determined by the LDH assay in uninfected HUVECs. NTZ cytotoxicity
was less than 5% if cells were treated with less than 10 μg/ml NTZ.
However, in concordance with the published results (Ashiru et al.,
2014), NTZ was cytostatic at concentrations higher than 3 μg/ml
(Fig. 2C–D). Therefore, we used NTZ at 2.5 μg/ml in most subsequent
experiments due to its low cytotoxicity, minimal effects on cell pro-
liferation, and inhibition of RV infection.
Next, we compared NTZ effectiveness in different cell types.
HUVEC, A549 and Vero cell monolayers were treated with 2-fold serial
dilutions of NTZ following RV-Dz infection at an MOI of 5, and viral
yields were determined at 48 hpi. The NTZ treatments resulted in a
dose-dependent inhibition of virus production in all cultures with
comparable IC50 values of 0.37 μg/ml [95% CI: 0.27–0.51], 0.44 μg/ml
[95% CI: 0.35–0.54], and 0.25 μg/ml [95% CI: 0.23–0.28] for A549,
Vero and HUVEC, respectively (Fig. 3). The average IC50 value of NTZ
against RV was 0.35 μg/ml (1.1 μM). The IC90 values were 4.17 μg/ml
[95% CI: 1.10–15.92] for A549, 2 μg/ml [95% CI: 1.07–3.73] for Vero
and 0.67 μg/ml [95% CI: 0.49–0.92] for HUVEC.
3.3. Effects of NTZ on replication of different RV strains
To determine whether NTZ inhibits infections with different RV
strains, we infected HUVEC monolayers with either the RA27/3 vaccine
strain or five wild type RVs representing currently circulating geno-
types. The infected cultures were treated with 2.5 μg/ml NTZ for 48 h
and then virus titers in the media was determined by a plaque assay
(Table 1). These data indicate that replication of different RV strains
was inhibited to a similar extent.
3.4. Effects of NTZ on low multiplicity infections
HUVECs were infected with RV-Dz or RA27/3 at an MOI of 0.05. At
this MOI only a few cells became infected initially. After virus ad-
sorption, the monolayers were treated with 1.25 or 2.5 μg/ml NTZ for 5
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days. Virus titers in the medium were determined by a plaque assay, the
percentage of infected cells estimated by IFA. Only a few infected cells
were detected in all NTZ-treated wells and the RV yield was sub-
stantially inhibited (Table 2). Thus, NTZ prevents RV replication and
spread in low multiplicity infections.
3.5. Effects of NTZ on different steps of RV replication
To identify the stage of the RV replication cycle affected by NTZ,
time-of-addition experiments were performed using RV infections at an
MOI of 5. HUVEC monolayers were treated with 2.5 μg/ml NTZ prior to
RV-Dz adsorption, during adsorption only, or post-adsorption. The NTZ
treatments prior to adsorption had no effect on RV replication (Fig. 4).
Minimal non-significant reduction of the RV yield was observed when
the drug was present during the adsorption step suggesting that NTZ
does not interfere with virus infectivity and cell entry. The most ef-
fective inhibition of RV replication was observed when the treatment
was initiated at the early stage of the replication cycle (0–6 hpi). Al-
though less effective, treatments initiated at the later stages (14–24 hpi)
were still able to significantly block virus production. These data sug-
gest that NTZ inhibits RV replication at more than one stage of the
replication cycle albeit with different efficiencies. However, there was
Fig. 2. Antiviral effects of NTZ against RV in HUVECs. Cell monolayers were infected with RV-Dz at an MOI of 5 and then treated with NTZ at the indicated concentrations or vehicle
control immediately after adsorption (Panels A and B). (A) Virus titer in the medium was determined at 48 hpi by a plaque assay. The data represent the means ± SD of two independent
experiments each done in duplicate. The dashed line shows the lower detection limit of the assay. (B) The monolayers (105 cells/well) were fixed at 48 hpi with methanol and
immunostained for E1. Nuclei were counterstained with DAPI. HUVECs were treated with different concentrations of NTZ for 48 h (Panels C and D). (C) Cytotoxicity and growth
inhibition were analyzed by a modified LDH assay. The data represent the means ± SD of two independent experiments each done in quadruplicate. (D) Phase contrast images of cells
showing the effect of different NTZ concentrations on cell viability.
Fig. 3. Dose-dependent effects of NTZ in different cells cultures. A549, Vero or HUVEC monolayers were infected with RV-Dz at an MOI of 5 and then treated with different concentrations
of NTZ immediately after virus adsorption. Virus titer in the medium was determined at 48 hpi by a plaque assay. RV-Dz titers in the DMSO-treated cultures (100%) were 7 × 105 (A549),
3 × 105 (Vero), and 6 × 104 (HUVEC). The data, which are expressed as a percentage of untreated control, represent the mean ± SD of two (A549 and Vero) or three (HUVEC)
independent experiments each done in duplicate. The dotted lines indicate the lC50 values.
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no effect if the drug was added at later times (48 hpi).
3.6. Effects of NTZ on synthesis and cellular distribution of RV structural
proteins
To assess the effect of NTZ treatment on virus protein synthesis,
mock infected or RV-Dz or RA27/3 infected HUVECs were treated with
0.5 and 1 μg/ml NTZ immediately after virus adsorption. At 48 hpi, RV
structural proteins were examined by WB analysis. Non-structural
proteins were not examined due to the lack of specific antibodies. Large
amounts of E1, E2 and C proteins were synthesized in the DMSO-treated
RV-Dz or RA27/3 infected cells (Fig. 5A, RV-Dz results are shown). A
dose-dependent reduction in viral protein production was observed in
the NTZ-treated infected cultures. The lack of changes in the band
pattern or band mobility suggested that NTZ does not substantially
affect post-translational modifications of the RV structural proteins.
To determine the effect of NTZ on the spatial distribution of RV
proteins in infected cells, HUVECs were treated with 1 μg/ml NTZ
following infection with RA27/3 at an MOI of 5. At 48 hpi, the RV
structural proteins were visualized in the infected cells by immuno-
fluorescence microscopy. There were no differences between the NTZ-
treated and control cells in diffuse distribution of C protein in the cy-
toplasm (not shown). Immunostaining for E1 showed minor changes
from tight perinuclear trans-Golgi localization in the control cells to
more diffuse perinuclear localization in the NTZ-treated cells (Fig. 5B).
The cellular distribution of E2 changed from a co-localization with E1
in the trans-Golgi in the control cells to a diffuse cytoplasmic dis-
tribution in many NTZ-treated cells. In some NTZ-treated cells E2
formed vesicular structures evenly distributed in the cytoplasm
(Fig. 5B). These data suggest that NTZ affects E1-E2 complex formation
and intracellular trafficking.
3.7. Effects of NTZ on RNA replication
To investigate whether NTZ effects RV genomic RNA synthesis, we
performed an RNA-FISH analysis of the RV-Dz and RA27/3 infected
HUVECs after the treatment with 2.5 μg/ml NTZ using the probe sets
specific for positive and negative RNA strands. RV + signal (> 50 dots/
cell) was detected in the infected control cells, but it was lacked or
substantially reduced in NTZ-treated cells (Fig. 6A–B). In accordance
with the reported results (Perelygina et al., 2015), only a 1–3 negative-
strand RNA molecules were detected in the control cultures, whereas
the RV- hybridization signal in the NTZ-treated cells was less than 1
dot/cell (Fig. 6A, RV-Dz results shown), which was the same as the
signal produced by the influenza probe set (not shown). These data
suggest that NTZ inhibits synthesis of the both positive and negative
strands of RV RNA.
Interestingly, the amounts of GAPDH mRNA (a positive assay con-
trol) were also substantially reduced in the NTZ-treated cultures
(Fig. 6A). We confirmed these results using a different reference gene,
β-actin (Fig. 6B). Quantitation of the fluorescence intensities by ImageJ
revealed 5–6 fold reduction of both GAPDH and β-actin RNA signals
(Fig. 6C). These results suggested either inhibition of cellular RNA
synthesis by NTZ or activation of an RNA degradation pathway such as
RNAseL. To further test this hypothesis, cell monolayers were treated
with either 5 μg/ml NTZ, 0.1% DMSO or 10 μg/ml actinomycin D
(inhibitor of cellular transcription) and then nascent RNA was fluor-
escently labeled using RNA-click chemistry. Analysis of microscopic
images showed that the size and fluorescence intensity in nucleoli
(region of ribosomal RNA synthesis) were decreased after the NTZ
treatment (Fig. 7A). Total nascent RNA levels per nucleus determined
by quantitation of the fluorescence intensity of nuclei (n = 50 for each
condition) with ImageJ were found to be reduced by ∼30% in the NTZ-
treated samples compared to the levels in the control samples (Fig. 7B).
Thus, NTZ inhibits synthesis of both viral and cellular RNA.
4. Discussion
We observed the apparent effectiveness of NTZ and the lack of ef-
fectiveness of interferon therapy in a single PID patient with severe skin
granulomas positive for RV antigen. Two-month peginterferon treat-
ment, which was given prior to NTZ, did not eliminate or reduce the
amount of RV antigen in the lesions of this patient. The inability of
interferon-alpha therapies to reduce RV excretion has been also re-
ported in infants with congenital rubella syndrome (Arvin et al., 1982).
Table 1
Sensitivities of vaccine and wild type strains of RV to NTZ (2.5 μg/ml).







a The data are mean of two independent experiments each performed in duplicate.
b Vaccine strain.
Table 2
NTZ antiviral effects on infections with low multiplicity (MOI = 0.05 pfu/ml).
RV strain NTZ Titerab Number (%) of infected/total cellsbc
μg/ml pfu/ml
RV-Dz 2.50 3 × 102 2/320 (0.6%)
1.25 1 × 103 2/218 (0.8%)
0.00 3 × 105 252/290 (86.9%)
RA27/3 2.50 < 102 3/339 (0.8%)
1.25 3 × 102 3/499 (0.6%)
0.00 5 × 103 110/440 (23%)
a The data are representative of 2 independent experiments, each performed in du-
plicate.
b Virus titer in the media and a number of infected cells were determined at 5 dpi, after
multiple rounds of virus replication.
c Infected cells were identified by immunostaining for the E1 protein of RV.
Fig. 4. Effect of NTZ treatment on different stages of RV infection. HUVECs were treated
with 2.5 μg/ml NTZ at the indicated times prior (pre, black bars), post infection (post,
white bars), or during adsorption only (Ad, the striped bar). The grey bar represents a
DMSO control. Virus titers in the medium were determined at 48 hpi (pre, Ad) or 48 h
post-treatment. The data represent the means ± SD of at least three independent ex-
periments each done in duplicate. *, p < 0.05; **, p < 0.01 compared with the DMSO-
treated cultures.
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Following treatment with 500 mg oral NTZ for two months, RV was
cleared from the wounds of the patient, but no clinical improvement
was observed. There are several possible reasons for that. First of all,
although the association between skin granulomas and RV infection has
been clearly demonstrated in individuals with some primary immune
deficiencies (Bodemer et al., 2014; Perelygina et al., 2016), the causal
role of RV infection in the formation of granulomas has not yet been
proven. However, the absence of RV RNA in the unaffected skin
((Bodemer et al., 2014); our unpublished observations) and detection of
RV in granulomas in the internal organs of some PID patients ((Neven
et al., 2017); our unpublished observations) suggest the causality. Of
course, with lesions that develop years or even decades after vaccina-
tion, causality determinations will likely require prospective studies
with long-term follow up. The patient had a very advanced/extensive
case. Her lesions had have persisted for more than a decade, and so one
would expect it to take a long time to reach complete clinical or his-
tological cure after elimination of the foreign antigen, at best. Fur-
thermore, this chronic infection may have caused long-term or,
Fig. 5. Effects of NTZ on RV proteins in HUVECs. (A) WB analysis of rubella structural proteins. HUVECs were infected with RV-Dz at an MOI of 5 or mock-infected and then exposed to
0.5 or 1 μg/ml NTZ or vehicle for 48 h. Proteins were extracted with RIPA buffer, separated by a 4–12% non-reducing NuPage gel, and then the blots were probed with rubella specific
antibodies to identify RV structural proteins E1, E2 and C (two C bands indicated by the arrows). The blots were also probed with β-actin MAb to demonstrate equal protein loading. (B)
Immunofluorescence analysis (at 2 dpi) of rubella structural proteins in the HUVEC monolayers that were treated with 1 μg/ml NTZ following infection with RA27/3 (MOI = 5 pfu/well).
Insert represents enlarged image of the E2 globular structures. Representative results of two independent experiments are shown in both A and B.
Fig. 6. Inhibition of genomic RV RNA synthesis by NTZ. HUVEC monolayers were infected with RV-Dz (A) or RA27/3 (B) at an MOI of 5 and then exposed to 2.5 μg/ml NTZ or vehicle for
48 h (A and B) Positive or negative strand RV RNA (red) and mRNA for GAPDH and β-actin (green) were detected by RNA-FISH. Nuclei were stained with DAPI. (C) Total fluorescence of
each of six randomly picked macroscopic fields per each condition was determined by using ImageJ. Data are presented as a mean ± SD of fluorescence intensity in arbitrary units (AU)
per a field. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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perhaps, permanent damage to the skin. In addition, secondary bac-
terial skin infection after the NTZ treatment may also have interfered
with the healing process. However, an NTZ treatment may be effective
in stopping the development in newly-formed lesions and preventing
RV spread and subsequent formation of granulomas in new locations.
We further confirmed NTZ anti-rubella activities in vitro and in-
vestigated molecular mechanisms of NTZ anti-rubella action using a cell
culture model. We documented a dose-dependent inhibitory effect of
NTZ on RV infection that is independent of viral strain. The IC50 value
was determined to be about 0.35 μg/ml (1.1 μM), which is similar to
NTZ IC50 values for other viruses such as influenza, coronavirus, or
hepatitis C (ranging from 0.2 to 1.5 μg/ml), indicating good antiviral
activity of the drug (Rossignol, 2014).
We also demonstrated that NTZ suppresses multiple post-entry
stages of RV infection as it was observed for other viruses (La Frazia
et al., 2013; Shi et al., 2014; Wang et al., 2016). It was more effective at
the early stages of the replication cycle and completely blocked RV
infection at 10 μg/ml, the peak concentration of the drug (Cmax) in
human plasma after receiving a single 500-mg oral dose of NTZ
(Broekhuysen et al., 2000); Alinia® package insert.
Presently, anti-viral mechanisms of NTZ are not fully elucidated.
Since NTZ inhibits replication of various DNA viruses and RNA viruses
that use different replication strategies, it was suggested that cellular
pathways (e.g., cap-mediated translation, ER-to-Golgi trafficking or
intracellular Ca2+ regulatory pathways) might be affected rather than
virus-specific targets (Ashiru et al., 2014; Elazar et al., 2009; Rossignol
et al., 2009). Here we show that the level of cellular RNA transcription
in NTZ-treated cells was reduced by more than 30% and the level of
some cellular mRNAs may drop several-fold.
We have also demonstrated that synthesis of both negative and
positive RNA strands of RV was substantially inhibited. Inhibition of
viral RNA replication by NTZ was also reported for Japanese en-
cephalitis (JE) virus (Shi et al., 2014). However, for other viruses, e.g.
influenza and hepatitis B virus, inhibition of synthesis of viral genomes
has not been detected and NTZ has been shown to act at post-transla-
tional level by blocking maturation and trafficking of envelope glyco-
proteins of these viruses (Rossignol et al., 2009; Stachulski et al., 2011).
Since viral RNA replication and transcription depend on multiple
Fig. 7. Inhibition of nascent cellular RNA synthesis by NTZ. (A) HUVEC monolayers were treated with 5 μg/ml of NTZ or DMSO for 24 h. For a positive control, the cells were treated with
an inhibitor of cellular RNA transcription, actinomycin D (ActD, 10 μg/ml) for 4 h. Following the treatments, the cells were metabolically labeled with 2 mM 5-ethynyl uridine. Newly
synthesized RNA was detected by using click chemistry with azide-derivatized Alexa Fluor 488. Images were acquired using a Zeiss fluorescent microscope. Inserts represent enlarged
images of the nuclei. Note the reduced total fluorescence intensity of the nuclei following the NTZ treatment in comparison to a vehicle control and the size reduction and dispersion of
nucleoli (ribosomal RNA) in the NTZ treated cells. (B) Total fluorescence of each nucleus was determined using ImageJ. The averages (n = 50 nuclei for each condition) and standard
deviation of the mean are shown. ****, p < 0.0001.
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cellular accessory proteins of the cellular RNA polymerase (Lai, 1998),
NTZ interference with viral and cellular RNA synthesis could be a
molecular mechanism that may mediate NTZ anti-viral actions against
RV, like JE.
Replication of RV RNA starts with the production of the negative-
strand RNA template and then switches to synthesis of positive-strand
genomic and subgenomic RNA at about 10 hpi (Liang and Gillam,
2001). RV was estimated to produce ∼ 1–4 copies of negative-strand
RNA per a cell (Perelygina et al., 2015) and thus negative-strand RNA
synthesis may be more sensitive to inhibitors of RNA replication than
positive-strand RNA synthesis. That could explain why NTZ was most
effective when administered soon after RV infection.
We also demonstrated that NTZ could block RV production at the
late stages of infection (14–24 hpi) probably by affecting E1-E2 com-
plex formation and/or ER-to-Golgi trafficking. E1 and E2 must form
correctly folded heterodimers in ER in order to be exported to the Golgi
where RV particles assemble (Hobman et al., 1993). NTZ was shown to
deplete Ca2+ in ER, resulting in perturbation of folding and maturation
of secreted and transmembrane proteins and their transfer within ER or
ER-Golgi export (Ashiru et al., 2014). We demonstrated the lack of a co-
localization of the large proportion of E2 with E1 suggesting perturbed
E1-E2 complex formation. Altered localization of structural proteins
would be anticipated to have negative effect on virion assembly. De-
spite its negative effects on multiple cellular pathways, a standard oral
dose of NTZ was well tolerated by the PID patient with RV positive
granuloma during two-month therapy. NTZ was shown to be safe for
both children and adults in several placebo-controlled clinical trials; the
rates of occurrence of adverse events did not differ significantly be-
tween NTZ and placebo treated groups (Amadi et al., 2002; Haffizulla
et al., 2014; Rossignol, 2014).
It is currently unclear whether the identified cellular mechanisms
were responsible for the reduction of RV antigen in the patient lesions.
For example, immunomodulatory effects of NTZ (Hong et al., 2012;
Trabattoni et al., 2016) may have played a role. Following oral ad-
ministration, NTZ is rapidly adsorbed in the gastrointestinal tract and
then hydrolyzed to form tizoxanide (desacetyl nitazoxanide), which is
further metabolized to form tizoxanide glucuronide (Broekhuysen et al.,
2000). Tizoxanide is at least as active in vitro as NTZ against different
viruses, while tizoxanide glucuronide exhibits only moderate antiviral
activities (Korba et al., 2008; La Frazia et al., 2013; Rossignol, 2009).
Second-generation thiazolides with favorable pharmacokinetics and
improved antiviral activities are currently under development and
evaluation (Keeffe and Rossignol, 2009). Future testing of active NTZ
metabolites and new generation thiazolides (e.g., RM-5038 and it active
derivative RM-4848) should aid in understanding of anti-RV mechan-
isms of thiazolides in vivo and in identification of the most effective
anti-RV compounds.
In conclusion, we have demonstrated that NTZ has a potent antiviral
activity against RV both in cell culture and in a single patient at the
doses used. Our data suggest multiple in vitro mechanisms of drug ac-
tion including inhibition of cellular and viral RNA synthesis and aber-
rant trafficking of viral structural proteins. NTZ could be the first drug
effective for the treatment of persistent rubella infections. The results of
this study suggest that further studies are warranted to evaluate the
ability of NTZ to control chronic rubella infections.
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